摘要
特应性皮炎(AD)是一种常见的慢性复发性炎症性皮肤病,往往有皮肤干燥、剧烈瘙痒和湿疹样皮疹等症状,降低患者的生活质量。度普利尤单抗是一种全人源单克隆抗体药物,可特异性结合白细胞介素(IL)-4从而抑制IL-4、IL-13的信号传导发挥治疗中重度AD的作用。在临床应用中,度普利尤单抗可能会引发一些罕见的不良反应,包括矛盾性反应,矛盾性反应为治疗过程中皮肤和其他器官出现新发皮损或原发部位皮损加剧等现象。现报道1例度普利尤单抗治疗AD并发矛盾性反应,本病例在使用生物制剂的过程中出现新发皮疹,考虑为生物制剂使用过程中出现的矛盾性反应。现将该病例的诊治过程进行报道并简要阐述其可能的机制,以帮助临床医生更加规范合理地运用生物制剂。
Atopic dermatitis(AD)is a common chronic recurrent inflammatory skin disease,which often has symptoms such as dry skin,severe itching and eczema-like rash,which reduces the quality of life(QoL)of patients.Dupilumab is a fully human monoclonal antibody drug,which can specifically bind to interleukin(IL)-4 to inhibit the signal transduction of IL-4 and IL-13,and play a role in the treatment of moderate and severe AD.In clinical application,dupilumab may cause some rare adverse reactions,including contradictory reactions,which are new skin lesions or aggravated skin lesions in the primary site during treatment.A case of atopic dermatitis complicated by contradictory reaction treated by dupilumab is reported.A new rash occurred in this case during the use of biological agents,which is considered as contradictory reaction during the use of biological agents.The diagnosis and treatment process of this case is reported in this paper and its possible mechanism is briefly expounded,so as to help clinicians use biological agents more standardized and reasonably.
作者
胡丽华
令狐月
张译
罗德苹
彭鑫尧
管连城
杨凡
HU Lihua;LINGHU Yue;ZHANG Yi;LUO Deping;PENG Xinyao;GUAN Liancheng;YANG Fan(Department of Dermatology,the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine,Guizhou,Guiyang 550000,China)
出处
《中国医药科学》
2025年第4期181-184,共4页
China Medicine And Pharmacy
基金
贵州省中医药管理局中医药、民族医药科学技术研究项目(QZYY-2023-048)
贵州中医药大学科研项目(贵中医科院内[2019]57号)。
